---
figid: PMC6347283__JME-18-0058fig1
figtitle: Representation of signaling pathways upstream of MTORC1
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC6347283
filename: JME-18-0058fig1.jpg
figlink: /pmc/articles/PMC6347283/figure/fig1/
number: F1
caption: 'Representation of signaling pathways upstream of MTORC1. MTOR exists in
  two functionally and structurally distinct complexes: MTORC1 and MTORC2. MTORC1
  is activated by hormones (e.g. insulin) or growth factors (e.g. EGF, FGF) via receptor
  tyrosine kinases. This sets off a signaling cascade leading to the activation of
  PI3K which inactivates TSC2 via AKT. In addition, TSC2 is inhibited by the MAPK/RSK
  pathway, and activated by DDIT4 and AMPK in response to hypoxia, and nutrient/energy
  depletion, respectively. TSC inactivation leads to MTORC1 activation, though the
  intermediary of RHEB. Amino acids stimulate LAMTOR, a GEF for the heterodimeric
  RRAG complex, which in turn activates MTORC1. Pharmacological inhibitors that potentially
  impact on the cross-talk between mTOR-dependent translational and metabolic programs
  are indicated. Further explanations are provided in the text. MTOR, mechanistic
  target of rapamycin kinase; MTORC1, mechanistic target of rapamycin complex 1; MTORC2,
  mechanistic target of rapamycin complex 2; EGF, epidermal growth factor; FGF, fibroblast
  growth factor; PI3K, phosphoinositide 3-kinase; TSC2, tuberous sclerosis complex
  2; MAPK, mitogen-activated protein kinase; RSK, p90 ribosomal S6 kinase; DDIT4,
  DNA damage inducible transcript 4; AKT, protein kinase B; AMPK, AMP-activated protein
  kinase; RHEB, ras homolog, MTORC1 binding; LAMTOR, late endosomal and lysosomal
  adaptor and MAPK (mitogen-activated protein kinase) and MTOR (mechanistic target
  of rapamycin) activator; GEF, guanine nucleotide exchange factor; RRAG, ras-related
  GTP-binding protein.'
papertitle: Oncogenic kinases and perturbations in protein synthesis machinery and
  energetics in neoplasia.
reftext: Oro Uchenunu, et al. J Mol Endocrinol. 2019 Feb;62(2):R83-R103.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9494144
figid_alias: PMC6347283__F1
figtype: Figure
redirect_from: /figures/PMC6347283__F1
ndex: 32db3833-def6-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6347283__JME-18-0058fig1.html
  '@type': Dataset
  description: 'Representation of signaling pathways upstream of MTORC1. MTOR exists
    in two functionally and structurally distinct complexes: MTORC1 and MTORC2. MTORC1
    is activated by hormones (e.g. insulin) or growth factors (e.g. EGF, FGF) via
    receptor tyrosine kinases. This sets off a signaling cascade leading to the activation
    of PI3K which inactivates TSC2 via AKT. In addition, TSC2 is inhibited by the
    MAPK/RSK pathway, and activated by DDIT4 and AMPK in response to hypoxia, and
    nutrient/energy depletion, respectively. TSC inactivation leads to MTORC1 activation,
    though the intermediary of RHEB. Amino acids stimulate LAMTOR, a GEF for the heterodimeric
    RRAG complex, which in turn activates MTORC1. Pharmacological inhibitors that
    potentially impact on the cross-talk between mTOR-dependent translational and
    metabolic programs are indicated. Further explanations are provided in the text.
    MTOR, mechanistic target of rapamycin kinase; MTORC1, mechanistic target of rapamycin
    complex 1; MTORC2, mechanistic target of rapamycin complex 2; EGF, epidermal growth
    factor; FGF, fibroblast growth factor; PI3K, phosphoinositide 3-kinase; TSC2,
    tuberous sclerosis complex 2; MAPK, mitogen-activated protein kinase; RSK, p90
    ribosomal S6 kinase; DDIT4, DNA damage inducible transcript 4; AKT, protein kinase
    B; AMPK, AMP-activated protein kinase; RHEB, ras homolog, MTORC1 binding; LAMTOR,
    late endosomal and lysosomal adaptor and MAPK (mitogen-activated protein kinase)
    and MTOR (mechanistic target of rapamycin) activator; GEF, guanine nucleotide
    exchange factor; RRAG, ras-related GTP-binding protein.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - AKT1
  - AKT2
  - AKT3
  - IRS1
  - PUM3
  - PCSK1N
  - TSPAN33
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - DDIT4
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - TSC1
  - CCL26
  - TSC2
  - TBC1D7
  - MAPKAP1
  - MTOR
  - RICTOR
  - MLST8
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - RRAGA
  - MAPK1
  - MAPK3
  - RRAGC
  - RHEB
  - RHEBP1
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - ATP8A2
  - APRT
  - MFAP1
  - PTEN
  - MAPK13
  - amino acids
  - Tyrosine
  - Vemurafenib
  - DGDP
  - Glucose
  - AMP
  - ATP
  - Biguanides
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
